PI Industries Ltd.
NSE: PIIND · Chemicals
Confirmed 31% profit collapse and 570 bps margin compression outweigh single product approval; no near-term recovery signal without Q2…
Pioxazon regulatory approval (September 2026) unlocks a new revenue stream after 10+ years R&D, and the $1.2B export order book provides a stable cash-generation floor independent of domestic agrochemical weakness.
FY26 net profit fell 31% YoY and Q1 FY27 EBITDA margins compressed 570 bps; stock underperformed NIFTY by 27.4 points over 12 months with no technical reversal signal (bearish EMA stack, RSI neutral at 48).
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bearish 28 Sep 2026 → now Scores 28 Oct 2026₹2,349.00 → ₹2,349.00 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →
Bullzeye Financial